NDR White Paper Issue 23: Horses to Humans thymopentin has value

Blog
- Jun 29, 2022
- 4 min
NDR White Paper Issue 21: Peptide Array Technology Provides a Cornerstone for ALS Research
- Jun 9, 2022
- 1 min
Bionox
- Jun 6, 2022
- 4 min
NDR White Paper Issue 20: Can Elamipretide target mitochondrial dysfunction in ALS?
- May 27, 2022
- 3 min
White Paper Issue 19: NDRs miRNA project
- May 23, 2022
- 9 min
White Paper Issue 18: Bringing Patients to Treatments
- Apr 6, 2022
- 3 min
White Paper Issue 17: Effectiveness of levamisole HCl and thymalfasin in two mouse models of ALS
- Mar 31, 2022
- 4 min
White Paper Issue 16: Seeing ALS
- Mar 27, 2022
- 4 min
White Paper Issue 15: Are in vitro Neuronal Cells Models for ALS discovery?
- Mar 2, 2022
- 6 min
White Paper Issue 14: Utility to Futility: Zilucoplan fails in human ALS trial
- Feb 17, 2022
- 3 min
White Paper Issue 13: NDR’s Roadmap to an ALS Cure
- Jan 10, 2022
- 3 min
NDR White Paper Issue 11: Mechanisms of common pathologies in ALS
- Jan 7, 2022
- 4 min
NDR White Paper Issue 10: Genetics and ALS
- Jan 5, 2021
- 1 min
White Paper Issue 9: Stress Response in ALS: Dr. Robert Naviaux
- Dec 26, 2020
- 4 min
NDR White Paper Issue 8: ALS and epigenetics
- Nov 20, 2020
- 7 min
NDR White Paper Issue 7: Models of ALS
- Nov 5, 2020
- 4 min
NDR White Paper Issue 6: Energy Metabolism
- Aug 28, 2020
- 3 min
NDR White Paper Issue 5: Activity of Thymosan
- Aug 4, 2020
- 4 min
NDR White Paper Issue 4: C9orf72